FIELD: biotechnology.
SUBSTANCE: proposed in vitro methods for predicting the risk of death within one year, based on the use of antibodies that bind with soluble human protein, Growth Stimulation-Expressed Gene 2 (ST2), or their antigen-binding fragments.
EFFECT: disclosed group of inventions can be used in medicine.
21 cl, 11 dwg, 10 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO SOLUBLE HUMAN ST-2 AND METHODS OF ANALYSIS | 2011 |
|
RU2625014C2 |
| METHODS FOR PREDICTING RISK OF DEVELOPING HYPERTENSION | 2013 |
|
RU2683026C2 |
| TEST APPARATUS AND METHODS FOR CARDIAC BIOLOGICAL MARKER ST2 | 2015 |
|
RU2702645C2 |
| CEACAM1 ANTIBODIES AND METHODS FOR USE THEREOF | 2010 |
|
RU2598710C2 |
| ANTIBODIES AGAINST IL-33, COMPOSITIONS, METHODS AND THEIR APPLICATION | 2017 |
|
RU2740309C2 |
| METHOD OF PAIN MANAGEMENT AND NEURON TISSUE INFLAMMATION TREATMENT WITH USING IL-31 ANTAGONISTS | 2007 |
|
RU2440130C2 |
| IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USING | 2006 |
|
RU2444528C2 |
| NOVEL ANTI-PD-L1 ANTIBODIES | 2016 |
|
RU2736151C2 |
| MONOCLONAL ANTIBODIES TO CD44, INTENDED FOR USE IN TREATING SQUAMOUS CELL CARCINOMA OF THE HEAD AND THE NECK | 2011 |
|
RU2599447C2 |
| SOLID PHASE ENZYME-IMMUNOASSAY (ELIZA) FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) | 2007 |
|
RU2517301C2 |
